Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC; CNTO1959PSA2001 Study Group.

Lancet. 2018 Jun 2;391(10136):2213-2224. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.

PMID:
29893222
2.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.

Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group.

Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24.

PMID:
28551073
3.

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.

Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, van Adelsberg J, Weinstein SP, Graham NM, Stahl N, Yancopoulos GD, Huizinga TW, van der Heijde D.

Arthritis Rheumatol. 2015 Jun;67(6):1424-37. doi: 10.1002/art.39093.

4.

MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.

Østergaard M, Jacobsson LT, Schaufelberger C, Hansen MS, Bijlsma JW, Dudek A, Rell-Bakalarska M, Staelens F, Haake R, Sundman-Engberg B, Bliddal H.

Ann Rheum Dis. 2015 Jun;74(6):1156-63. doi: 10.1136/annrheumdis-2014-206359. Epub 2014 Dec 15.

5.

Tofacitinib versus methotrexate in rheumatoid arthritis.

Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF; ORAL Start Investigators.

N Engl J Med. 2014 Jun 19;370(25):2377-86. doi: 10.1056/NEJMoa1310476.

6.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group.

Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30.

7.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group.

Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13.

PMID:
23769296
8.

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators.

N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072. Erratum in: N Engl J Med. 2013 Jul 18;369(3):293.

9.

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

Baranauskaite A, Raffayová H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N; RESPOND investigators.

Ann Rheum Dis. 2012 Apr;71(4):541-8. doi: 10.1136/ard.2011.152223. Epub 2011 Oct 12.

10.

Differential association of juvenile and adult systemic lupus erythematosus with genetic variants of oestrogen receptors alpha and beta.

Kisiel BM, Kosinska J, Wierzbowska M, Rutkowska-Sak L, Musiej-Nowakowska E, Wudarski M, Olesinska M, Krajewski P, Lacki J, Rell-Bakalarska M, Jagodzinski PP, Tlustochowicz W, Ploski R.

Lupus. 2011 Jan;20(1):85-9. doi: 10.1177/0961203310381514. Epub 2010 Oct 20.

PMID:
20961965
11.

[Influence of genetic factors on development and severity of rheumatoid arthritis--part I].

Trefler J, Paradowska-Gorycka A, Matyska-Piekarska E, Rell-Bakalarska M, Wojciechowska B, Łacki JK.

Pol Merkur Lekarski. 2009 Aug;27(158):157-60. Review. Polish.

PMID:
19856886
12.

Psychological stress in rheumatoid arthritis patients: a comparative Polish-German study: summary of the current conceptualization of the role of stress in rheumatoid arthritis.

Bugajska J, Brzosko M, Jedryka-Góral A, Głuszko P, Zołnierczyk-Zreda D, Sagan A, Konarska M, Rell-Bakalarska M, Pazdur J, Zeidler H, Rihl M; PGG-SES-AIMs.

Autoimmun Rev. 2010 Feb;9(4):211-5. doi: 10.1016/j.autrev.2009.08.005. Epub 2009 Aug 19.

PMID:
19698804
13.

Still's disease in patient with silicone breast implants: case report.

Błasiak A, Błachowicz A, Gietka A, Rell-Bakalarska M, Franek E.

Pol Arch Med Wewn. 2008 Jan-Feb;118(1-2):65-7.

14.

[Preliminary data concerning cross-reacting anticardiolipin antibodies as potential inhibiting endotoxin activity factors].

Zabek J, Noworyta J, Brasse-Rumin M, Pyka J, Krzewska I, Rell-Bakalarska M.

Pol Arch Med Wewn. 2006 May;115(5):452-6. Polish.

PMID:
17195360
15.

[Inhibition of cardiolipin binding antibodies from synovial fluids of patients with arthritis by endotoxin].

Zabek J, Noworyta J, Brasse-Rumin M, Rell-Bakalarska M.

Pol Arch Med Wewn. 2006 May;115(5):447-51. Polish.

PMID:
17195359
16.

Occupational work and quality of life in osteoarthritis patients.

Łastowiecka E, Bugajska J, Najmiec A, Rell-Bakalarska M, Bownik I, Jedryka-Góral A.

Rheumatol Int. 2006 Dec;27(2):131-9. Epub 2006 Nov 9.

PMID:
17094005
17.

Work ability in ageing workers suffering from chronic diseases.

Jedryka-Góral A, Bugajska J, Łastowiecka E, Najmiec A, Rell-Bakalarska M, Bownik I, Michalak JM, Kochmański M.

Int J Occup Saf Ergon. 2006;12(1):17-30.

PMID:
16553997
18.

The effect of taurine chloramine on pro-inflammatory cytokine production by peripheral blood mononuclear cells isolated from rheumatoid arthritis and osteoarthritis patients.

Chorazy-Massalska M, Kontny E, Kornatka A, Rell-Bakalarska M, Marcinkiewicz J, Maśliński W.

Clin Exp Rheumatol. 2004 Nov-Dec;22(6):692-8.

PMID:
15638042
19.

High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.

Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W.

Arthritis Rheum. 2002 Jul;46(7):1744-53.

20.

Isoprinosine in the early pre-erosive stage of rheumatoid arthritis: a pilot study.

Sadowska-Wróblewska M, Wróblewska-Graff T, Weryńska-Przybylska J, Rell-Bakalarska M, Kurdybacha J.

Z Rheumatol. 1988 Mar-Apr;47(2):113-6.

PMID:
2455393

Supplemental Content

Loading ...
Support Center